Prime Minister Narendra Modi will review Pune, Ahmedabad, and Hyderabad today and review the works related to the Covid-19 vaccine being developed there.
New Delhi: PM Narendra Modi will visit Pune, Ahmedabad, and Hyderabad on Saturday and review the works related to the Covid-19 vaccine being developed there. The Prime Minister’s Office (PMO) gave this information. The PMO tweeted, ‘PM Narendra Modi will visit three cities to personally review the vaccine development and manufacturing process. He will visit Zydus Cadila Park in Ahmedabad, Bharat Biotech in Hyderabad, and Serum Institute of India in Pune.
On Twitter, the Prime Minister’s Office tweeted, “Prime Minister Modi will visit three cities tomorrow to take stock of vaccine development and processes. He will visit Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad, and Serum Institute in Pune.” This is the Prime Minister’s first visit to these institutions after starting the vaccine production.
Serum Institute is said to be at the forefront of producing the covishield vaccine. After getting emergency approval, it will be applied to India as well. Bharat Biotech Covaxin is also undergoing final phase trials. It is being told that the vaccine may be available by February 2021. The Zydus Cadila vaccine is currently undergoing a second trial. This vaccine may reach people by May.
Oxford and AstraZeneca’s vaccine at the Serum Institute of India in Pune is at the forefront of the covidshield race. Whereas Oxford University and Estrogenica, the manufacturer of this vaccine, have finished the third phase trial in other countries and sent the proposal to the UK authority for vaccine approval.
This vaccine was successful in the Phase-3 trial by about 94 percent, but the ears of scientists stood up when the initial data in stage 3 of the trial showed 2 different effects. The Oxford AstraZeneca vaccine was found to be 90% effective in one method of vaccine dosing and 62% effective in the other method. This is the reason that the company has once again made up its mind to investigate.
Human trials of the third phase of an indigenous biotech vaccine have started. It has been approved by the Drug Controller General of India. In the Phase III trial, this dose of covaxin will be given to about 28,500 people aged 18 years or above. The trial of covaxin has started at AIIMS, Delhi, one of the most trusted hospitals in the country.